Search Events:
Sep 27, 2018
CMC Pharma Regulations MasterClass
Vienna, Wien
Conference Details
Begins:
Sep 27, 2018
End:
Sep 28, 2018
Conference Location:
Conference Organizer
Conference Organizer:
Global Leading Conferences
Contact Person:
Milu Sini Lal
Phone Number:
+36 1 858 05 60
Overview
We are organizing the CMC Pharma Regulations MasterClass on the 27th and 28thof September, 2018 in Vienna, Austria, led by Dr Andreu Soldevila, CEO of Leanbio. The CMC Pharma Regulations MasterClass will provide a deep and detailed instruction on Chemistry, Manufacturing and Controls (CMC) requirements and review processes for the clinical trial, registration and post-approval drug applications.
By the end of the MasterClass, the participants will understand:
i) Process development strategies
ii) Analytical and Formulation development
iii) GMP manufacture
iv) Process analytical Technology
v) Guidelines and Regulatory pathways for New Biological entities and Biosimilars
For the training description, detailed trainer profile and training program, please request the Training Agenda.
ulatory pathways for New Biological entities and Biosimilars
For the training description, detailed trainer profile and training program, please request the Training Agenda.
We are organizing the CMC Pharma Regulations MasterClass on the 27th and 28thof September, 2018 in Vienna, Austria, led by Dr Andreu Soldevila, CEO of Leanbio. The CMC Pharma Regulations MasterClass will provide a deep and detailed instruction on Chemistry, Manufacturing and Controls (CMC) requirements and review processes for the clinical trial, registration and post-approval drug applications.
By the end of the MasterClass, the participants will understand:
i) Process development strategies
ii) Analytical and Formulation development
iii) GMP manufacture
iv) Process analytical Technology
v) Guidelines and Regulatory pathways for New Biological entities and Biosimilars
For the training description, detailed trainer profile and training program, please request the Training Agenda.
ulatory pathways for New Biological entities and Biosimilars
For the training description, detailed trainer profile and training program, please request the Training Agenda.
